IgA Nephropathy

A Phase 3, Randomized, Double-Blind,Placebo-Controlled Study of Povetacicept in Adults with IgA Nephropathy (Rainier)

Protocol Name: A Phase 3, Randomized, Double-Blind,Placebo-Controlled Study of Povetacicept in Adults with IgA Nephropathy (Rainier) Sponsor: Alpine Immune Sciences / Vertex Indication: IgA Nephropathy GFR: ≥30 DETAILS >

A Phase 3, Randomized, Double-Blind,Placebo-Controlled Study of Povetacicept in Adults with IgA Nephropathy (Rainier) Read More »

Efficacy and safety of extended TARPEYO® treatment >9 months in adult patients with primary IgA nephropathy

Protocol Name: Efficacy and safety of extended TARPEYO® treatment >9 months in adult patients with primary IgA nephropathy Sponsor: Calliditas Indication: IgA Nephropathy DETAILS >

Efficacy and safety of extended TARPEYO® treatment >9 months in adult patients with primary IgA nephropathy Read More »